The AI-driven HART CVE blood test has been demonstrated to be highly accurate in determining whether a person with diabetes will have a heart attack or major cardiac event within the next year. Data presented at the recent American College of Cardiology (ACC) Scientific Sessions suggests the HART CVE blood test significantly improves risk classification of patients with diabetes, allowing for more aggressive therapy in higher-risk patients and avoiding expensive or invasive treatment in lower-risk patients.
Cardiologists from Massachusetts General Hospital tested 450 subjects to predict one-year risk of heart attack, stroke, or cardiovascular death in patients with diabetes. When the test score was divided into low-risk and high-risk categories, the test showed a highly accurate Hazard Ratio (HR) of 25, meaning that a high-risk patient with diabetes has 25 times the risk for a major cardiac event within one year as compared to low-risk patients without diabetes.
“This multiple protein, weighted risk test provides improved accuracy as compared to clinical risk factors and could be particularly useful for patients with diabetes who also have suspected or known stable and acute heart disease, for which there are very few prognostic risk models,” said James L Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “In addition to leading to more appropriate care of patients with diabetes, it could also have a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”
In addition to the HART CVE test for one-year risk of a major cardiac event, Prevencio, the company behind the solution, offers a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy).
“Prevencio is grateful for our collaboration with Massachusetts General Hospital, and we look forward to ongoing improvement in patient care,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio. “Our mission is to provide clinicians with safer, more accurate, and more affordable ways to identify and treat the tens of millions of patients with diabetes and cardiac issues.”
Cardiovascular disease is the leading cause of death in the US and globally. Additionally, diabetes was the seventh leading cause of death in the US in 2017 and is believed to be underreported as a cause of death. Patients with diabetes have twice the rate of cardiovascular disease as compared to patients without diabetes. According to the American Diabetes Association, 34.2 million Americans or 10.5% of the population had diabetes in 2018, costing $327 billion in healthcare expenditures.
The post AI-driven blood test highly accurate heart attack and stroke prediction appeared first on AIMed.
Author: